# reMYND NV

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/remynd

- Industry: Pharmaceuticals
- Headquarters: Leuven, Belgium
- Website: www.remynd.com
- Total disclosed funding: $27M
- Latest round: Series B (Aug 1, 2020)
- Investors on record: 6

## About

reMYND NV specializes in developing groundbreaking oral treatments focused on restoring neuronal functionality in patients with neurodegenerative diseases, including Alzheimer's and Huntington's disease.Founded in 2002 in Leuven, Belgium, reMYND NV is dedicated to addressing age-related neurodegenerative diseases through innovative therapies. The company has undergone strategic pivots, including an emphasis on developing a contract research organization (CRO) division to collaborate with global pharmaceutical firms. The founder, Joris Winderickx, has a history in the biotech space, although further details about previous ventures are not specified. The company has raised a total of EUR 12 million in its Series B funding round as of January 21, 2021, primarily from investors including Preventive Cardiology Inc. and BNP Paribas Fortis.reMYND focuses on first-in-class oral treatments for neurodegenerative diseases, particularly Alzheimer’s and Huntington’s disease. Their innovative therapeutics aim to restore synaptic function and mitigate amyloid-beta and tau pathologies. The company also explores mitochondrial dysfunction related to Amyotrophic Lateral Sclerosis (ALS). Their CRO division offers services to major pharmaceutical companies, assessing treatment effects through proprietary mouse models.In the most recent year, reMYND reported revenue of EUR 9,480,130.60, with an EBITDA loss of EUR 1,940,031.10 for the year 2022. Revenue is generated through partnerships with pharmaceutical companies for research services that support the development of neurodegenerative disease treatments.Following the successful completion of a EUR 12 million Series B funding round in January 2021, reMYND plans to utilize the funds to finalize proof-of-concept clinical trials for its Alzheimer’s and diabetes programs in 2022. The company is also exploring strategic expansions into new geographical markets to bolster its research capabilities and strengthen partnerships with pharmaceutical entities.

## Funding rounds

- Series B, Aug 1, 2020, $18M — K.U. Leuven Research & Development, BNP Paribas Fortis, Korys, PMV, KU Leuven University, Preventive Cardiology Inc.
- Series B, Nov 13, 2018, $8.6M — K.U. Leuven Research & Development, BNP Paribas Fortis, Korys, PMV, KU Leuven University

## Investors

- K.U. Leuven Research & Development (https://capitalatlas.ai/funds/k-u-leuven-research-development) — Series B
- BNP Paribas Fortis — Series B
- Korys (https://capitalatlas.ai/funds/korys) — Series B
- PMV (https://capitalatlas.ai/funds/pmv) — Series B
- KU Leuven University — Series B
- Preventive Cardiology Inc. — Series B